Related Experiment Videos
Novel biological immunotherapies for psoriasis
Jean Kanitakis1, Agripina Cristina Butnaru, Alain Claudy
1Department of Dermatology and INSERM U346, Ed Herriot Hospital (Pav. R), 69437 Lyon cx 03, France. kanitakis@lyon.inserm.fr
Psoriasis is a common skin disease affecting 1 - 3% of the white population. Although its physiopathogenesis still remains poorly understood, recent data suggest a key role played by memory T cells in the genesis of skin and joint lesions. Recent developments in the understanding of cellular mechanisms underlying psoriasis and in biotechnologies have given rise to a generation of biological agents that have shown clinical efficacy in treating psoriasis. These agents, including chimeric antibodies, fusion proteins and recombinant interleukins, specifically target the activated memory T cells directly involved in the development of psoriasis lesions and inhibit their action either directly or through inhibition of pro-inflammatory cytokines. Compared with conventional systemic treatments, they show a better safety profile and allow durable remissions. Some of these agents were very recently marketed for the treatment of psoriasis and hopefully others will follow. These biologicals have opened a new era for the management of this disease; they are reviewed in this article, based on data available in the literature.
Psoriasis is a common skin disease affecting 1 - 3% of the white population. Although its physiopathogenesis still remains poorly understood, recent data suggest a key role played by memory T cells in the genesis of skin and joint lesions. Recent developments in the understanding of cellular mechanisms underlying psoriasis and in biotechnologies have given rise to a generation of biological agents that have shown clinical efficacy in treating psoriasis. These agents, including chimeric antibodies, fusion proteins and recombinant interleukins, specifically target the activated memory T cells directly involved in the development of psoriasis lesions and inhibit their action either directly or through inhibition of pro-inflammatory cytokines. Compared with conventional systemic treatments, they show a better safety profile and allow durable remissions. Some of these agents were very recently marketed for the treatment of psoriasis and hopefully others will follow. These biologicals have opened a new era for the management of this disease; they are reviewed in this article, based on data available in the literature.
Related Concept Videos
Tumor Immunotherapy
EPS and iPS Cells in Disease Research
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
iPS Cell Differentiation
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents